Novavax, Inc. (NASDAQ:NVAX – Get Rating) – Analysts at Zacks Research issued their FY2025 earnings per share estimates for Novavax in a report released on Wednesday, March 15th. Zacks Research analyst S. Ganoria expects that the biopharmaceutical company will post earnings per share of $1.87 for the year. The consensus estimate for Novavax’s current full-year earnings is ($5.00) per share.
Novavax (NASDAQ:NVAX – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. The biopharmaceutical company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($1.36). The firm had revenue of $357.40 million during the quarter, compared to analysts’ expectations of $383.14 million. During the same quarter in the prior year, the firm posted ($11.18) earnings per share. The firm’s quarterly revenue was up 60.8% on a year-over-year basis.
Novavax Stock Down 0.3 %
NVAX stock opened at $5.95 on Friday. Novavax has a twelve month low of $5.68 and a twelve month high of $85.60. The stock has a market cap of $512.73 million, a P/E ratio of -0.71 and a beta of 1.78. The business’s 50-day moving average price is $9.74 and its 200-day moving average price is $16.26.
Institutional Trading of Novavax
Large investors have recently added to or reduced their stakes in the company. Neo Ivy Capital Management bought a new stake in Novavax in the 3rd quarter worth approximately $37,000. Money Concepts Capital Corp bought a new stake in Novavax in the 4th quarter worth approximately $37,000. CI Investments Inc. increased its stake in Novavax by 1,572.8% in the 4th quarter. CI Investments Inc. now owns 3,747 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 3,523 shares during the last quarter. Credit Agricole S A increased its stake in Novavax by 65.8% in the 3rd quarter. Credit Agricole S A now owns 2,520 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 1,000 shares during the last quarter. Finally, IFP Advisors Inc increased its stake in Novavax by 328.3% in the 4th quarter. IFP Advisors Inc now owns 6,994 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 5,361 shares during the last quarter. Institutional investors own 45.70% of the company’s stock.
Novavax Company Profile
Novavax, Inc Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.